Copper is a potent inhibitor of both the canonical and non-canonical NFκB pathways

Cell Cycle

Volumn 13, Issue 6, 2014, Pages 1006-1014

  Kenneth, Niall S ^a   Hucks Jr , George E ^a   Kocab, Andrew J ^a   McCollom, Annie L ^a   Duckett, Colin S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clioquinol; Copper; NF B; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; CD30 ANTIGEN; CLIOQUINOL; COPPER; I KAPPA B ALPHA; IONOPHORE; PROTEIN P100; REACTIVE OXYGEN METABOLITE; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; COPPER METABOLISM; DNA BINDING; DOWN REGULATION; EMBRYO; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY;

CLIOQUINOL; COPPER; NFΚB; REACTIVE OXYGEN SPECIES;

ACETYLCYSTEINE; ANIMALS; CELL LINE; CELL LINE, TUMOR; CLIOQUINOL; COPPER; FREE RADICAL SCAVENGERS; HUMANS; I-KAPPA B PROTEINS; IONOPHORES; MICE; NF-KAPPA B; OXIDATIVE STRESS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84897996996     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27922     Document Type: Article

References (39)

1. Madsen E, Gitlin JD. Copper deficiency. Curr Opin Gastroenterol 2007; 23:187-92; PMID:17268249; http://dx.doi.org/10.1097/MOG.0b013e32801421bb
2. Kim BE, Nevitt T, Thiele DJ. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 2008; 4:176-85; PMID:18277979; http://dx.doi.org/10.1038/nchembio.72
3. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 1999; 284:805-8; PMID:10221913; http://dx.doi.org/10.1126/ science.284.5415.805
4. Tisato F, Marzano C, Porchia M, Pellei M, Santini C. Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev 2010; 30:708-49; PMID:19626597
5. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009; 35:32-46; PMID:18774652; http://dx.doi.org/10.1016/j.ctrv.2008.07.004
6. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 2003; 1:701-6; PMID:12939395
7. Goodman VL, Brewer GJ, Merajver SD. Copper deficiency as an anti-cancer strategy. Endocr Relat Cancer 2004; 11:255-63; PMID:15163301; http://dx.doi.org/10.1677/erc.0.0110255
8. DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev 2012; 246:379-400; PMID:22435567; http://dx.doi.org/10.1111/j.1600-065X.2012.01099.x
9. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 2012; 12:121-32; PMID:22257950
10. Ghosh S, Hayden MS. Celebrating 25 years of NF-κ B research. Immunol Rev 2012; 246:5-13; PMID:22435544; http://dx.doi.org/10.1111/j.1600- 065X.2012.01111.x
11. Ramakrishnan P, Baltimore D. Sam68 is required for both NF-κB activation and apoptosis signaling by the TNF receptor. Mol Cell 2011; 43:167-79; PMID:21620750; http://dx.doi.org/10.1016/j.molcel.2011.05.007
12. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104:504-11; PMID:12584750; http://dx.doi.org/10. 1002/ijc.10972
13. Guo X, Xu B, Pandey S, Goessl E, Brown J, Armesilla AL, Darling JL, Wang W. Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett 2010; 290:104-13; PMID:19782464; http://dx.doi.org/10.1016/j.canlet.2009. 09.002
14. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006; 66:10425-33; PMID:17079463; http://dx.doi.org/10.1158/0008- 5472.CAN-06-2126
15. McElwee MK, Song MO, Freedman JH. Copper activation of NF-kappaB signaling in HepG2 cells. J Mol Biol 2009; 393:1013-21; PMID:19747488; http://dx.doi.org/10.1016/j.jmb.2009.08.077
16. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 2006; 281:17670-80; PMID:16648635; http://dx.doi.org/10. 1074/jbc.M602487200
17. Versieck J, Cornelis R. Normal levels of trace elements in human blood or serum. Anal Chim Acta 1980; 116:217-54; http://dx.doi.org/10.1016/S0003- 2670(01)95205-5
18. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000; 96:4307-12; PMID:11110706
19. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem 2007; 282:10252-62; PMID:17261581; http://dx.doi.org/10.1074/jbc.M608817200
20. Pineda-Molina E, Klatt P, Vázquez J, Marina A, García de Lacoba M, Pérez-Sala D, Lamas S. Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry 2001; 40:14134-42; PMID:11714266; http://dx.doi.org/10.1021/bi011459o
21. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132:344-62; PMID:18267068; http://dx.doi.org/10.1016/j.cell.2008.01.020
22. Schimmer AD, Jitkova Y, Gronda M, Wang Z, Brandwein J, Chen C, Gupta V, Schuh A, Yee K, Chen J, et al. A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. Clin Lymphoma Myeloma Leuk 2012; 12:330-6; PMID:22683301; http://dx.doi.org/10.1016/j.clml.2012.05.005
23. Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res 2005; 65:3389-95; PMID:15833873
24. Mao X, Li X, Sprangers R, Wang X, Venugopal A, Wood T, Zhang Y, Kuntz DA, Coe E, Trudel S, et al. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia 2009; 23:585-90; PMID:18754030; http://dx.doi.org/10.1038/leu.2008.232
25. Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP, Dou QP. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 2007; 67:1636-44; PMID:17308104; http://dx.doi.org/10.1158/0008-5472.CAN-06-3546
26. Zhai S, Yang L, Cui QC, Sun Y, Dou QP, Yan B. Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. J Biol Inorg Chem 2010; 15:259-69; PMID:19809836; http://dx.doi.org/10.1007/s00775-009-0594-5
27. Schmitt SM, Frezza M, Dou QP. New applications of old metal-binding drugs in the treatment of human cancer. [Schol Ed]. Front Biosci (Schol Ed) 2012; 4:375-91; PMID:22202066
28. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005; 7:R897-908; PMID:16280039; http://dx.doi.org/10.1186/bcr1322
29. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011; 103:1007-17; PMID:21606441; http://dx.doi.org/10.1093/jnci/djr160
30. DiDonato JA, Mercurio F, Karin M. Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol Cell Biol 1995; 15:1302-11; PMID:7862124
31. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268:726-31; PMID:7732382; http://dx.doi.org/10.1126/science.7732382
32. Cater MA, Haupt Y. Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer. Biochem J 2011; 436:481-91; PMID:21426304; http://dx.doi.org/ 10.1042/BJ20110123
33. Mufti AR, Burstein E, Csomos RA, Graf PC, Wilkinson JC, Dick RD, Challa M, Son JK, Bratton SB, Su GL, et al. XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol Cell 2006; 21:775-85; PMID:16543147; http://dx.doi.org/10.1016/j.molcel.2006.01.033
34. Wu ZH, Wong ET, Shi Y, Niu J, Chen Z, Miyamoto S, Tergaonkar V. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell 2010; 40:75-86; PMID:20932476; http://dx.doi.org/10.1016/j.molcel.2010.09.010
35. Beug ST, Cheung HH, LaCasse EC, Korneluk RG. Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol 2012; 33:535-45; PMID:22836014; http://dx.doi.org/10.1016/j.it.2012.06.004
36. Formigari A, Gregianin E, Irato P. The effect of zinc and the role of p53 in copper-induced cellular stress responses. J Appl Toxicol 2013; 33:527-36; PMID:23401182; http://dx.doi.org/10.1002/jat.2854
37. Rotilio G, Carrì MT, Rossi L, Ciriolo MR. Copper-dependent oxidative stress and neurodegeneration. IUBMB Life 2000; 50:309-14; PMID:11327325; http://dx.doi.org/10.1080/15216540051081074
38. Khan G, Merajver S. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs 2009; 18:541-8; PMID:19335282; http://dx.doi.org/10.1517/13543780902845622
39. Rumble JM, Bertrand MJ, Csomos RA, Wright CW, Albert L, Mak TW, Barker PA, Duckett CS. Apoptotic sensitivity of murine IAP-deficient cells. Biochem J 2008; 415:21-5; PMID:18684108; http://dx.doi.org/10.1042/BJ20081188